"Vidarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Descriptor ID |
D014740
|
MeSH Number(s) |
D03.633.100.759.590.138.900 D13.570.065.950 D13.570.583.138.900
|
Concept/Terms |
Vidarabine- Vidarabine
- beta-Ara A
- beta Ara A
- Adenine Arabinoside
- Arabinoside, Adenine
- alpha-D-Arabinofuranosyladenine
- alpha D Arabinofuranosyladenine
- Ara A
- alpha-Ara A
- alpha Ara A
- Arabinofuranosyladenine
- Arabinosyladenine
- 9-beta-D-Arabinofuranosyladenine
- 9 beta D Arabinofuranosyladenine
- 9-beta-Arabinofuranosyladenine
- 9 beta Arabinofuranosyladenine
- Ara-A
|
Below are MeSH descriptors whose meaning is more general than "Vidarabine".
Below are MeSH descriptors whose meaning is more specific than "Vidarabine".
This graph shows the total number of publications written about "Vidarabine" by people in this website by year, and whether "Vidarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 0 | 1 |
2007 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vidarabine" by people in Profiles.
-
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2008 Mar; 22(3):585-92.
-
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005 Sep 15; 106(6):2018-25.